Product labels may refer to vinpocetine as “Vinca minor extract,” “lesser periwinkle extract,” or “common periwinkle extract.”
Vinpocetine decreased fetal weight and increased the chances of a miscarriage in test animals, according to the report. Blood levels measured in the pregnant animals were similar to those reported in people after taking a single dose of vinpocetine, indicating that pregnant women may experience adverse effects from vinpocetine similar to those seen in the pregnant animals. Toxicology tests also proved that in a significant number of products, the actual content of vinpocetine varied from what was stated on the label; this could result in higher doses than what is recommended.
Manufacturers and distributors of dietary supplements and dietary ingredients are “responsible for evaluating the safety and labeling of their products before marketing” to ensure that they meet all federal requirements, according to the agency’s website. “FDA is responsible for taking action against any adulterated or misbranded dietary supplement product after it reaches the market.” This means the FDA has not reviewed each individual vinpocetine dietary supplement or its labeling before the product has become available to consumers.
Along with a warning for pregnant women, the FDA is also advising manufacturers to evaluate their vinpocetine supplement labeling “to ensure that it provides safety warnings against use by pregnant women and women who could become pregnant,” the FDA stated.